Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia
- 13 January 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (5), 1267-1270
- https://doi.org/10.1080/10428194.2020.1856832
Abstract
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by the reciprocal translocation of t(15;17) (q22;q21) encoding the promyelocytic leukemia–retinoic acid...This publication has 14 references indexed in Scilit:
- Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabBlood, 2017
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 TrialJournal of Clinical Oncology, 2017
- First experience of the AML‐Berlin‐Frankfurt‐Münster group in pediatric patients with standard‐risk acute promyelocytic leukemia treated with arsenic trioxide and all‐trans retinoid acidPediatric Blood & Cancer, 2017
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialThe Lancet Oncology, 2015
- ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTSMediterranean Journal of Hematology and Infectious Diseases, 2014
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaThe New England Journal of Medicine, 2013
- Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemiaBlood, 2010
- GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in childrenBlood, 2005
- Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experienceLeukemia, 2004
- Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed PatientsBlood, 1997